Welcome
Support Centre
30 August 2008 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
UKCTG
mental health register
archived registers
all registers
tips on searching
 
Registration
submit trials
 
Information
about mRCT
mRCT FAQs
data items
memorandum
contributors

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ ...Back to search results ] [ Print-friendly version ]
Fermentation and cardiovascular risk factors
Source of recordUK Clinical Trials Gateway
ISRCTNISRCTN35312139
Date ISRCTN assigned02/08/2007
Local reference number(s)NS1
Public titleFermentation and cardiovascular risk factors
Scientific title
AcronymN/A
Disease/condition/study domainType 2 diabetes/ obesity
Study hypothesisThat consuming a fermentable carbohydrate will improve indices of insulin sensitivity in individuals with insulin resistance.
Design/methodologyRandomised, parallel, single-blind dietary intervention.
Research ethics reviewCentral Office of Research Ethics Committees (COREC) and the University of Surrey Ethics Committee, approved on 26th June 2006 (REC ref: O6/Q1909/30)
Countries of trialUnited Kingdom
Participants - inclusion criteria1. Healthy
2. Fasting insulin >60 pmol/l
2. Male and female 18-60 years
Participants - exclusion criteria1. Cardiovascular or endocrine diseases
2. Medication likely to affects either lipid or glucose metabolism
Patient information material
Anticipated start date01/11/2006
Anticipated end date30/10/2008
Status of trialOngoing
Target number of participants45
InterventionsDietary supplementation with either 0 g, 20 g or 40 g resistant starch per day for 12 weeks.
Primary outcome measure(s)Insulin sensitivity will be assessed before and after the 12-week intervention by the following:
1. Euglycaemic-hyperinsulinaemic clamp
2. Liver fat content measured by Magnetic Resonance Imaging [MRI]
Secondary outcome measure(s)The following outcomes are being measured before and after the 12-week intervention:
1. Endothelial function, assessed by Pulse Wave Velocity (PWV) and 24-hour blood pressure recordings
2. Blood inflammatory markers
Sources of fundingNational Starch and Chemical Company (International)
Sponsor nameUniversity of Surrey (UK)
Sponsor detailsResearch and Enterprise Support
Nodus Centre
University of Surrey
Guildford
United Kingdom
GU2 7XH
Sponsor websitehttp://www.surrey.ac.uk/
Contact nameDr Denise Robertson
Contact detailsBiomedical and Molecular Sciences
University of Surrey
Guildford
United Kingdom
GU2 7XH
More informationFor more up-to-date information please go to the ISRCTN link below.
Link to record in ISRCTN RegisterISRCTN35312139
Date last extracted from ISRCTN register17/04/2008
Submit your trial protocol Top studies in medical research Submit to Trials journal
terms & conditions | privacy statement | © Current Controlled Trials Ltd


BioMed Central